Yael Kenen
Directeur Technique/Scientifique/R&D chez EPITOMEE MEDICAL LTD
Profil
Yael Kenen is currently the Vice President-Clinical Affairs at Epitomee Medical Ltd.
Prior to this, Yael worked as the Chief Executive Officer at Lacrima Medical Ltd.
and as the Chief Operating Officer at TransPharma Medical Ltd.
Yael holds an MBA from Technion-Israel Institute of Technology and a doctorate from The Hebrew University of Jerusalem.
Postes actifs de Yael Kenen
| Sociétés | Poste | Début |
|---|---|---|
| EPITOMEE MEDICAL LTD | Directeur Technique/Scientifique/R&D | 01/01/2020 |
Anciens postes connus de Yael Kenen
| Sociétés | Poste | Fin |
|---|---|---|
Lacrima Medical Ltd.
 Lacrima Medical Ltd. Medical SpecialtiesHealth Technology Lacrima Medical Ltd. engages in the development of medical device for the treatment of chronic insomnia. The company was founded in 2013 and is headquartered in Tel Aviv, Israel. | Directeur Général | - |
TransPharma Medical Ltd.
 TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Directeur des opérations | - |
Formation de Yael Kenen
| The Hebrew University of Jerusalem | Doctorate Degree |
| Technion-Israel Institute of Technology | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EPITOMEE MEDICAL LTD | Health Technology |
| Entreprise privées | 2 |
|---|---|
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Health Technology |
Lacrima Medical Ltd.
Lacrima Medical Ltd. Medical SpecialtiesHealth Technology Lacrima Medical Ltd. engages in the development of medical device for the treatment of chronic insomnia. The company was founded in 2013 and is headquartered in Tel Aviv, Israel. | Health Technology |
